Attenuation effects of heparin-superoxide dismutase conjugate on bleomycin-induced lung fibrosis in vivo and radiation-induced inflammatory cytokine expression in vitro.
In this study, the effects of heparin-superoxide dismutase conjugate (heparin-SOD) on bleomycin-induced pulmonary fibrosis in vivo and on inflammatory cytokine expression in vitro were evaluated. To investigate the effects of heparin-SOD on pulmonary fibrosis, heparin-SOD was administered to bleomycin (BLM)-treated mice by intraperitoneal injection once a day and the hydroxyproline content in lung was determined per 7days. The degree of fibrosis was assessed quantitatively using histopathologic features. The results showed that heparin-SOD inhibited BLM-induced lung fibrotic lesions as reflected by the decrease of lung hydroxyproline content and lung fibrosis grade 28days after BLM instillation. The in vitro effects on the cytokine level expressed by irradiated 3T3 fibroblasts showed that heparin-SOD significantly lowered the levels of transforming growth factor-beta1 and interleukin-1beta. These results strongly demonstrated that heparin-SOD might be useful in the prevention and treatment of pulmonary fibrosis.
Liu
Jinfeng
J
Institute of Biochemical and Biotechnological Drugs, School of Pharmaceutical Science, Shandong University, Wenhuaxilu 44, Jinan 250012, PR China.
Wang
Xuan
X
Wang
Fengshan
F
Teng
Li
L
Cao
Jichao
J
D000818:Animals; D001761:Bleomycin; D002478:Cells, Cultured; D004195:Disease Models, Animal; D005347:Fibroblasts / Q000187:drug effects* / Q000378:metabolism / Q000528:radiation effects; D015870:Gene Expression; D006493:Heparin / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000627:therapeutic use; D006909:Hydroxyproline / Q000378:metabolism; D007249:Inflammation / Q000378:metabolism / Q000473:pathology; D053583:Interleukin-1beta / Q000096:biosynthesis*; D008168:Lung / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008297:Male; D051379:Mice; D011658:Pulmonary Fibrosis / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D013482:Superoxide Dismutase / Q000494:pharmacology* / Q000627:therapeutic use; D053773:Transforming Growth Factor beta1 / Q000096:biosynthesis*; D014965:X-Rays
D053583:Interleukin-1beta; D053773:Transforming Growth Factor beta1; D001761:Bleomycin; D006493:Heparin; D013482:Superoxide Dismutase; D006909:Hydroxyproline